SLC5A2 and type 2 diabetes mellitus: Other SGLT2 inhibitors, such as Canagliflozin, has been shown to significantly reduce cardiovascular death, nonfatal myocardial infarction, and stroke in type 2 diabetes patients, while also alleviating symptoms of HF [13,23].